TLDR External factors can cause skin cancer cells that usually don't spread to grow and form tumors in mice.
The study investigated the behavior of Ptch mutant basal cell carcinoma (BCC) precursors in mice and found that their spread was physiologically suppressed, which counteracted tumor formation. This suppression mechanism was crucial in preventing BCC development, suggesting potential therapeutic targets. The research indicated that a homozygous Ptch mutation alone was insufficient for BCC development without external stimuli, highlighting the complexity of BCC pathogenesis. The study used a sample size of 13 mice and emphasized the need for new BCC models and treatment strategies.
6 citations,
December 2019 in “Frontiers in genetics” GLI1 might protect against the start of skin cancer and is not linked to cancer severity.
11 citations,
March 2014 in “Journal of Investigative Dermatology” Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.
176 citations,
February 2006 in “Cancer Research” Patched1 helps prevent tumors by controlling cell growth.
The document concludes that the development of certain tumors is influenced by genetic background and that a specific gene modification can lead to tumor regression and reduced growth.
11 citations,
March 2014 in “Journal of Investigative Dermatology” Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.
June 2019 in “International journal of dermatology and venereology” The Hedgehog Signaling Pathway is important for skin and hair development and skin cancer treatment, but more research is needed to understand it fully.
17 citations,
June 2017 in “British Journal of Dermatology” The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.
8 citations,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.